This article is more than 5 years old. Information may no longer be current.
FDA warns about breast cancer treatments, grants soft tissue sarcoma therapy orphan drug status – top stories in hematology/oncology
The FDA’s warning that some breast cancer treatments could cause severe lung inflammation and the announcement that it granted orphan drug status to a T-cell therapy for soft tissue sarcoma were among the top stories in hematology/oncology last week.
Other top stories included a pilot study that found without chemotherapy, a targeted therapy was able to induce pathological complete response in women who had operable breast cancer with germline BRCA mutations.
FDA warns breast cancer treatments may lead to rare but severe lung inflammation
The FDA issued a safety alert indicating that three drugs used to treat some patients with advanced breast cancer may cause rare but severe lung inflammation. Read more.
T-cell therapy receives FDA’s orphan drug status for soft tissue sarcoma
The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the treatment of soft tissue sarcomas. Read more.
Nivolumab confers fivefold improvement in overall survival vs. chemotherapy in advanced non-small cell lung cancer
BARCELONA —Nivolumab led to a fivefold improvement in overall survival at 5 years compared with docetaxel among patients with previously treated advanced non-small cell lung cancer, according to pooled results from the CheckMate 017 and 057 trials presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. Read more.
Neoadjuvant talazoparib induces pathologic complete response in BRCA -mutated operable breast cancer
Neoadjuvant talazoparib without chemotherapy induced a high rate of pathologic complete response among women with operable breast cancer who harbored germline BRCA mutations, according to results of a small single-arm pilot study published in Journal of Clinical Oncology. Read more.
Novel KRAS inhibitor induces disease control in 96% of treated patients with non-small cell lung cancer
BARCELONA — AMG 510 appeared well-tolerated and showed promising antitumor activity among patients with locally advanced or metastatic non-small cell lung cancer, with 96% of patients achieving disease control, according to phase 1 study results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. Read more.